UNASSIGNED: Therefore, we report our experience of GVHD prophylaxis regimen combining PT-Cy and tacrolimus with addition of post-engraftment low-dose anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation from haplo-identical donors (Haplo). Sixtyseven patients were included in the analysis. All patients received myeloablative or intensified sequential conditioning regimen.
UNASSIGNED: The median follow-up was 521 (range, 10~991) days. The cumulative incidences of 100-day grade II-IV acute GVHD was 14.9±4.4%, and no case of grade III-IV acute GVHD was documented. The cumulative incidences of 2-yearchronic GVHD and moderate-to-severe chronic GVHD were 25.4±5.4% and 11.9±4%, respectively. The non-relapse mortality at day+100 and 2year were 7.5±3.2% and 9.0±3.5%, respectively. The cumulative incidence of relapse at 2year was 16±6.4%. The 2-year probability of DFS and OS were 73.8% (95%CI, 61.5~88.4%) and 72.5% (95% CI, 57.1~92.1%), respectively. The 2-year GRFS was estimated as 63.6% (95%CI, 50.6~80%).
UNASSIGNED: Our results suggested that a combination of PT-Cy, tacrolimus, and low-dose post-engraftment ATG was a promising GVHD prophylaxis with low incidence of acute GVHD in the haplo-transplantation setting.
■因此,我们报告了在来自单plo相同供体(Haplo)的异基因干细胞移植中,PT-Cy和他克莫司联合移植后低剂量抗胸腺细胞球蛋白(ATG)的GVHD预防方案的经验.67名患者被纳入分析。所有患者均接受清髓性或强化序贯预处理方案。
■中位随访时间为521(范围,10~991)天。100天II-IV级急性GVHD的累积发生率为14.9±4.4%,无III-IV级急性GVHD病例记录.2年慢性GVHD和中重度慢性GVHD的累积发病率分别为25.4±5.4%和11.9±4%,分别。第100天和第2年的非复发死亡率分别为7.5±3.2%和9.0±3.5%,分别。2年累积复发率为16±6.4%。DFS和OS的2年概率分别为73.8%(95CI,61.5~88.4%)和72.5%(95%CI,57.1~92.1%),分别。2年GRFS估计为63.6%(95CI,50.6~80%)。
■我们的结果表明,PT-Cy的组合,他克莫司,低剂量移植后ATG是一种有前景的GVHD预防方法,在单倍体移植环境中急性GVHD发生率低.